Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea

Chest

Volumn 145, Issue 3, 2014, Pages 525-533

  Minville Dr , Caroline ^a,b   Hilleret Dr , Marie Noëlle ^b   Tamisier, Renaud ^b   Aron Wisnewsky, Judith ^c   Clement, Karine ^a   Trocme, Candice ^b,d   Borel, Jean Christian ^b   Lévy, Patrick ^b   Zarski Dr , Jean Pierre ^b   Pépin, Jean Louis ^b  

^a LAVAL UNIVERSITY   (Canada)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPOXIA; INSULIN RESISTANCE; LIVER FIBROSIS; MALE; MORBID OBESITY; NOCTURNAL HYPOXIA; NONALCOHOLIC FATTY LIVER; OXYGEN SATURATION; PRIORITY JOURNAL; SLEEP DISORDERED BREATHING; SLEEP TIME; TRIACYLGLYCEROL BLOOD LEVEL;

ANOXIA; ENDOTHELIUM, VASCULAR; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN RESISTANCE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SLEEP APNEA, OBSTRUCTIVE; VASODILATION;

EID: 84896693460     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0938     Document Type: Article

References (52)

1. Aron-Wisnewsky J, Minville C, Tordjman J, et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol. 2012; 56 (1):225-233.
2. Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, et al; Spanish Sleep and Breathing Network. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA. 2012; 307 (20):2161-2168.
3. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012; 33 (10):1190-1200.
4. Baguet JP, Barone-Rochette G, Tamisier R, Levy P, Pépin JL. Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol. 2012;9(12):679-688.
5. Tanné F, Gagnadoux F, Chazouillères O, et al. Chronic liver injury during obstructive sleep apnea. Hepatology. 2005; 41 (6):1290-1296.
6. Jouët P, Sabaté JM, Maillard D, et al. Relationship between obstructive sleep apnea and liver abnormalities in morbidly obese patients: a prospective Study. Obes Surg. 2007; 17 (4):478-485.
7. Tatsumi K, Saibara T. Effects of obstructive sleep apnea syndrome on hepatic steatosis and nonalcoholic steatohepatitis. Hepatol Res. 2005; 33 (2):100-104.
8. Savransky V, Nanayakkara A, Vivero A, et al. Chronic intermittent hypoxia predisposes to liver injury. Hepatology. 2007; 45 (4):1007-1013.
9. Pépin JL, Tamisier R, Lévy P. Obstructive sleep apnoea and metabolic syndrome: put CPAP efficacy in a more realistic perspective. Thorax. 2012; 67 (12):1025-1027.
10. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007; 115 (10):1285-1295.
11. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010;31 (9):1142-1148.
12. Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function: from research into clinical practice. Circulation. 2012; 126 (6):753-767.
13. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986; 2 (2):165-173.
14. Ratziu V, Charlotte F, Heurtier A, et al LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005; 128 (7):1898-1906
15. The Lancet. Time for action in New York on non-communicable diseases. Lancet. 2011; 378 (9795):961.
16. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58(5):1007-1019.
17. Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010; 51 (3):828-835.
18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24 (2):289-293.
19. Poynard T, Lassailly G, Diaz E, et al FLIP Consortium. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS ONE. 2012; 7 (3):e30325.
20. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective Study. Lancet. 2001; 357 (9262):1069-1075.
21. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003; 39 (2):222-230.
22. Naveau S, Raynard B, Ratziu V, et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol. 2005; 3 (2):167-174.
23. Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol. 2005; 4:10.
24. Poynard T, Ratziu V, Charlotte F, et al LIDO Study Group; CYTOL Study Group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006; 6:34.
25. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010; 31 (9):1142-1148.
26. Argod J, Pépin JL, Lévy P. Differentiating obstructive and central sleep respiratory events through pulse transit time. Am J Respir Crit Care Med. 1998; 158 (6):1778-1783.
27. Berry RB, Budhiraja R, Gottlieb DJ, et al American Academy of Sleep Medicine; Deliberations of the Sleep Apnea Defi-nitions Task Force of the American Academy of Sleep Medicine. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. J Clin Sleep Med. 2012; 8 (5):597-619.
28. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106 (25):3143-3421.
29. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011; 332 (6037): 1519-1523.
30. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesisof nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010; 52 (2):774-788.
31. Piguet AC, Stroka D, Zimmermann A, Dufour JF. Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. Clin Sci (Lond). 2010; 118 (6):401-410.
32. Savransky V, Jun J, Li J, et al. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ Res. 2008; 103 (10):1173-1180.
33. Li J, Thorne LN, Punjabi NM, et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res. 2005; 97 (7):698-706.
34. Drager LF, Li J, Shin MK, et al. Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates adipose lipoprotein lipase in a mouse model of sleep apnoea. Eur Heart J. 2012; 33 (6):783-790.
35. Musso G, Olivetti C, Cassader M, Gambino R. Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: emerging evidence and mechanisms. Semin Liver Dis. 2012; 32 (1):49-64.
36. Mishra P, Nugent C, Afendy A, et al. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int. 2008; 28 (8): 1080-1086.
37. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology. 2005; 42 (3):650-656.
38. Norman D, Bardwell WA, Arosemena F, et al. Serum aminotransferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep. 2008; 31 (1):121-126.
39. Türkay C, Ozol D, Kasapoǧlu B, Kirbas I, Yildirim Z, Yiǧitoǧlu R. Infl uence of obstructive sleep apnea on fatty liver disease: role of chronic intermittent hypoxia. Respir Care. 2012; 57 (2):244-249.
40. Verhulst SL, Jacobs S, Aerts L, et al. Sleep-disordered breathing: a new risk factor of suspected fatty liver disease in overweight children and adolescents? Sleep Breath. 2009; 13 (2):207-210.
41. Drager LF, Li J, Reinke C, Bevans-Fonti S, Jun JC, Polotsky VY. Intermittent hypoxia exacerbates metabolic effects of dietinduced obesity. Obesity (Silver Spring). 2011; 19 (11): 2167- 2174.
42. Chatterjee S, Ganini D, Tokar EJ, et al. Leptin is key to peroxynitrite- mediated oxidative stress and Kupffer cell activation in experimental nonalcoholic steatohepatitis. J Hepatol. 2013;58(4):778-784.
43. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation. 2008; 117 (19):2467-2474.
44. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health Study. Circulation. 2010; 122 (4):352-360.
45. Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med. 2002; 165 (5):677-682.
46. Harsch IA, Schahin SP, Radespiel-Tröger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med. 2004; 169 (2):156-162.
47. Lavie L, Lavie P. Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J. 2009; 33 (6):1467-1484.
48. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profi le in nonalcoholic fatty liver disease. Hepatology. 2005; 42 (2):473-480.
49. Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010; 254 (2):393-400.
50. Hallsworth K, Hollingsworth KG, Thoma C, et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol. 2013; 58 (4):757-762.
51. Kheirandish-Gozal L, Sans Capdevila O, Kheirandish E, Gozal D. Elevated serum aminotransferase levels in children at risk for obstructive sleep apnea. Chest. 2008; 133 (1):92-99.
52. Kohler M, Pepperell JC, Davies RJ, Stradling JR. Continuous positive airway pressure and liver enzymes in obstructive sleep apnoea: data from a randomized controlled trial. Respiration. 2009; 78 (2):141-146.